Pilot Study of Safety and Efficacy of Spheramine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-02-29

Study Completion Date

2012-05-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tolerability and Efficacy of Spheramine will be evaluated after operative implantation (Stereotactic Intrastriatal Implantation) in patients with advanced Parkinson's Disease

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

STEPS Trial - Spheramine Safety and Efficacy Study

NCT00206687

Parkinson Disease

TERMINATED PHASE2

SHARPEN - Parkinson's Disease Dementia

NCT05987540

Parkinson Disease Dementia

TERMINATED NA

Study to Assess the Safety and Effects of Autologous Adipose-Derived SVF Cells in Patients With Parkinson's Disease

NCT01453803

Parkinson's Disease

WITHDRAWN NA

A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin

NCT00148369

Idiopathic Parkinson's Disease

COMPLETED

Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease

NCT00643890

Parkinson's Disease

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson''s Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Group Type EXPERIMENTAL

Spheramine (BAY86-5280)

Intervention Type BIOLOGICAL

Stereotactic Intrastriatal Implantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spheramine (BAY86-5280)

Stereotactic Intrastriatal Implantation

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Idiopathic Parkinson's disease (PD). As defined by:

* presence of bradykinesia and either rest tremor or rigidity
* history of asymmetry of PD signs
* history of progression of PD signs, and
* no other suspected cause of PD signs
* Patient is between 40 and 70 years of age, inclusive
* Patient is L-dopa-sensitive and has unequivocal clinical "off" periods as documented by home diary, completed on 4 consecutive days with an average of 1.5 hours/day in the clinically "off" state
* Patient is Hoehn \& Yahr stage III or higher in the practically defined "off" phase
* All other medical problems are stable or under control and are not contraindications to general anesthesia or stereotactic neurosurgery
* Patient's brain magnetic imaging resonance (MRI) shows no abnormality that would contraindicate Spheramine implantation
* Patient does not have a major psychiatric problem or dementia
* Patient must give written informed consent to participate in this study
* Patient must be on a stable dose of antiparkinsonian medication for at least 1 month prior to completion of the home diary assessment and the baseline UPDRS assessments
* If the patient is a woman of childbearing potential, she must not be nursing or pregnant and must use an adequate form of birth control for the duration of the study deemed appropriate by the investigator such as oral contraceptives, IUD, or condoms
* Patient must be living with or in close constant contact with a person who can contribute information as to the patient's condition before and after implant and provide assistance, if necessary

Exclusion Criteria

* Patients with atypical Parkinson's disease (e.g. parkinsonian "plus" syndrome, secondary Parkinsonian syndrome)
* Patients exhibiting only a tremor-based symptomatology
* Patients exhibiting very severe dyskinesias (lasting more than 2 hour/day) exacerbated by L-dopa, evaluated as 4/4 on the dyskinesia scale (violent dyskinesias, incompatible with any normal motor task)
* Women of childbearing potential without contraception
* Patients who are non-cooperative or incapable of completing self-evaluation scales or diaries
* Patients presenting with known pharmacologic immunosuppression related to chemotherapeutic treatment for malignancy, autoimmune disease, allografts or other medical conditions associated with immunosuppression
* Patient's cardiovascular, pulmonary, renal and hematological state contraindicates use of general anesthesia
* Evidence of abnormal coagulation including PT \> 13 sec, PT \> 35 sec or platelets \< 5 ml
* Patients having had previous stereotactic brain surgery
* Patients treated by apomorphine pump
* Patients with significant cognitive impairment, untreated or treatment resistant depression, psychosis, hallucinations or delusions that would prevent their effective participation in the study
* Patients who have participated in another experimental drug or device trial in the past 30 days

Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No